Optimizing Neutropenia Management With Sacituzumab Govitecan

The panel takes a deeper look at neutropenia, one of the adverse events of special interest with sacituzumab govitecan. Panelists discuss the frequency of higher-grade neutropenia and the importance of proactive management, reviewing how current labeling frames prophylactic growth factor use for patients at increased risk and why predicting risk can be challenging in the first-line setting. The conversation explores the practical complexity introduced by the day 1 and day 8 dosing schedule, including how the timing of long- versus short-acting growth factor support is chosen, and references trial experience informing these approaches. Panelists emphasize the clinical relevance of neutropenia by noting reported infection-related events in the trial setting, often where growth factor support was not used, underscoring the value of proactive prophylaxis. The discussion also touches on emerging interest in UGT1A1 polymorphisms as a way to identify more vulnerable patients. Viewers gain actionable strategies for managing this toxicity.